Yinhua CSI HK Equities Medical and Health Integration ETF

Nomura Downgrades China Biologic Products Target Price to HKD 8.3

Stone Pharmaceutics Receives Clinical Trial Approval Notice for Daratumumab Injection

Shanghai Market Supervision Administration Enforcement Team Signs Compliance System Construction Cooperation Memorandum with Innovent Biologics

Influenza Epidemic Leads to Surge in Demand for Anti-Influenza Drugs

Sontek, China Pharmaceutical, and Huidai Acquisition-Z Disclose Latest Shareholder Rights

Chinese Innovative Pharmaceutical Companies Discuss Overseas Strategies: From 'Riding Others' Ships' to 'Building Their Own Ships'

Chairman Cai Dongchen of Stone Pharmaceutical Group Increased Shareholding to 25.26%

China's Pharmaceutical Industry Transforms into a Global Innovation Hub

Jade Pharmaceutical's SYH2085 Approved for Clinical Trials in China

JD Health Launches Billion-Yuan Brand Alliance for Digital Upgrade of Corporate Health Consumption Market

WuXi Biologics Receives CDP Climate Change and Water Security 'A' Rating

JPMorgan Sees Opportunities in China's Healthcare Sector, Recommends Biotech and CXO Stocks

Sukoddju Injection Phase III Clinical Trial Achieves Positive Results for Severe Plaque Psoriasis Treatment

Morgan Stanley Downgrades JP Group’s Target Price and Adjusts Profit Projections

Glenmark Pharmaceuticals Ltd Secures Exclusive Rights to Aumolertinib from Hansoh Pharmaceutical

Hansoh Pharmaceutical's Wholly-owned Subsidiary Enters into Exclusive Licensing, Collaboration and Distribution Agreement for Amivantamab with Glenmark

Cancer Biologics Kangdein Biotech Makes Multiple Progresses in Core Product Pipeline

Innovent Biologics' Masdutide Receives Approval from Macau's Drug Regulatory Authority

Morgan Stanley Raises Target Price for AliHuang to HKD 4.6

JD Health Announces New Progress in Tumor Prevention and Treatment with Medical Large Models

01072

02979

01093

01709

00293

03899

02546

00695

02579

03939

DONGFANG ELEC(01072) rose 8.17%, with a trading turnover 699.2 Million HKD, and a year-to-date rose 180.2%. WANGUO GOLD GP(02979) rose 8.05%, with a trading turnover 12.8 Million HKD, and a year-to-date rose 207.1%. CSPC PHARMA(01093) rose 7.64%, with a trading turnover 2.8 Billion HKD, and a year-to-date rose 95.6%.

Top Gainers & Losers

DONGFANG ELEC

WANGUO GOLD GP

CSPC PHARMA

DL HOLDINGS GP

CATHAY PAC AIR

CIMC ENRIC

ZHIHUI MINING

DONGWU CEMENT

CNGR

Top 10 HK Stock Gainers (12.23)

01787

01772

01818

06936

02050

01880

09660

01024

06613

CSPC PHARMA(01093) rose 7.64%, with a trading turnover 2.8 Billion HKD, and a year-to-date rose 95.6%. SD GOLD(01787) rose 4.64%, with a trading turnover 586.1 Million HKD, and a year-to-date rose 210.2%. SANHUA(02050) fell 6.55%, with a trading turnover 2.0 Billion HKD, and a year-to-date rose 47.8%. CTG DUTY-FREE(01880) fell 4.4%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 51.4%.

- The Hang Seng Index fell by 0.11% but has gained 28.5% year-to-date, while the Hang Seng Tech Index decreased by 0.69% with a year-to-date increase of 22.8%.  
- Sihuan Pharmaceutical (01093) rose 7.64% with a trading volume of HKD 2.76 billion, reflecting a 95.6% increase for the year, and Shandong Gold (01787) increased by 4.64% with a volume of HKD 590 million, showing a remarkable 210.2% year-to-date gain.  
- However, Sanhua Intelligent Control (02050) dropped 6.55% amidst a trading volume of HKD 2 billion, resulting in a 47.8% increase this year, while China National Pharmaceutical (01880) fell 4.4% with a trading volume of HKD 1.05 billion, still up 51.4% year-to-date.

SD GOLD

GANFENGLITHIUM

ZHAOJIN MINING

SF HOLDING

SANHUA

CTG DUTY-FREE

HORIZONROBOT-W

KUAISHOU-W

Lens

Top 5 HK Stock Gainers/Losers (>100B) (12.23)

00241

Alibaba Health Information Technology Limited announced that CEO Shen Difan will also become Chairman and head of the Nomination Committee, effective December 15, 2025. This consolidation of leadership roles deviates from Hong Kong's corporate governance code, raising governance concerns. While the market reaction has been contained, the concentration of power is a risk factor for investors. The company's shares are potentially undervalued by 38%, with fair value estimates suggesting significant upside. Investors are advised to consider governance risks alongside potential growth opportunities.

Simplywall

ALI HEALTH

How Investors May Respond To Alibaba Health Information Technology (SEHK:241) CEO Shen Difan Also Becoming Chairman